Category Archives: Ventricular Remodeling

LONDON, EnglandPatients with pulmonary hypertension (PH) undergoing TAVR for severe symptomatic aortic stenosis fare significantly worse than those without increased pre-interventional pulmonary pressures, a new analysis shows. After a mean follow-up of 31 months, patients with PH, which was defined as a mean pulmonary arterial pressure (mPAP) > 25 mm Hg, had a 60% increased risk of all-cause mortality compared with those without PH, reported Dionysios Adamopoulos, MD (Geneva University Hospital, Switzerland), last week at PCR London Valves 2019. Continue reading →

No one knows when the next market crash is coming. Continue reading →

Oleg F Sharifov,1 Thomas S Denney Jr,2 J Michael Wells,1,3,4 Gregory A Payne,1,4 Swati Gulati,1,3 Himanshu Gupta,5 Mark T Dransfield,1,3,4 Steven G Lloyd1,4 1Department of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA; 2Department of Electrical and Computer Engineering, Auburn University, Auburn, AL, USA; 3UAB Lung Health Center, Birmingham, AL, USA; 4Birmingham VA Medical Center, Birmingham, AL, USA; 5Advanced Cardiovascular Imaging, Valley Medical Group, Paramus, NJ, USA Correspondence: Steven G Lloyd Department of Medicine, University of Alabama at Birmingham, 1808 7th Avenue South, BDB 201, Birmingham, AL 35294-0012, USA Tel +1 205 934 9736 Fax +1 205 934 9730 Email slloyd@uabmc.edu Pulmonary hypertension (PH) is an important prognostic indicator in patients with chronic obstructive pulmonary disease (COPD); however, PH in these patients is typically mild-to-moderate severity and invasive testing is not typically utilized.1 Though echocardiography can be used to screen for PH, it has limited accuracy in measuring pulmonary artery (PA) pressure and often hindered by window limitations in COPD patients.2 Cardiovascular magnetic resonance (CMR) does not have window limitations and can accurately evaluate the right ventricular (RV) and PA function. Therefore, there is a growing interest in the use of CMR for the diagnosis and management of PH, including patients with lung diseases Continue reading →

TMRR, in its recent market report, suggests that the Cardiac Restoration Systems market report is set to exceed US$ xx Mn/Bn by 2029. The report finds that the Cardiac Restoration Systems market registered ~US$ xx Mn/Bn in 2018 and is spectated to grow at a healthy CAGR over the foreseeable period. This Cardiac Restoration Systems market study considers 2018 as the base year, 2019 as the estimated year, and 2019 2029 as the forecast timeframe. Continue reading →

SOUTH SAN FRANCISCO Dec 2, 2019 (Thomson StreetEvents) -- Edited Transcript of MyoKardia Inc earnings conference call or presentation Monday, November 11, 2019 at 1:30:00pm GMT MyoKardia, Inc. - SVP of Clinical Development MyoKardia, Inc. - SVP of Medical Sciences MyoKardia, Inc. Continue reading →

As Biotechnology businesses, BioLineRx Ltd. (NASDAQ:BLRX) and Moderna Inc. (NASDAQ:MRNA), are affected by compare. Continue reading →

GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ -- Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced the completion of enrollment and dosing in its Phase 1 trial of INXN-4001, a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure, the leading cause of death worldwide. The Phase 1 open label study is designed to investigate the safety of INXN-4001 delivered via Retrograde Coronary Sinus Infusion (RCSI) in patients with an implanted Left Ventricular Assist Device (LVAD) for mechanical support of end-stage heart failure, either as a bridge to transplant or destination therapy (clinical trial identifier: NCT03409627) Continue reading →

BioLineRx Ltd. (NASDAQ:BLRX) and Cyanotech Corporation (NASDAQ:CYAN) are two firms in the Biotechnology that compete against each other Continue reading →

This is a contrast between BioLineRx Ltd. (NASDAQ:BLRX) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) based on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. Continue reading →

BioLineRx Ltd. (NASDAQ:BLRX) and Edge Therapeutics Inc Continue reading →